
The study revealed that statin use may reduce the risk of colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD), a high-risk population. A study of 10,546 participants demonstrated that statin users exhibited a 24% lower incidence of CRC and reduced CRC-related and all-cause mortality. Benefits appeared to increase with prolonged statin use. These findings underscore the potential protective role of statins against CRC in IBD patients.
Like
Save
Share